AVANOS MEDICAL (AVNS) Company Report

Avanos Medical (AVNS) reaffirmed its full-year sales guidance of $690-$700 million and adjusted EPS of $0.85-$0.95, expecting to finish at the higher end of sales guidance.
The company aims to become a $1 billion business by 2030, driven by accelerating growth in its Specialty Nutrition Systems and Pain Management and Recovery segments, synergistic M&A, and operational efficiency.
Strategic initiatives include realizing $15-$20 million in cost savings by 2026 and mitigating tariff impacts by exiting China by mid-2026.
Avanos' M&A strategy, exemplified by the Nexus acquisition in September 2025 which generated $5 million in revenue over four months, focuses on acquiring at least one deal annually worth $20 million or more to support revenue growth.

Jan 13, 2026, 10:15 PM

Transcript

Avanos Medical Reaffirms Guidance and Outlines Strategic Growth Plan

AVNS

Guidance Update

M&A

New Projects/Investments

Avanos Medical reaffirmed its full-year guidance for sales between $690 million and $700 million, expecting to finish at the upper end, and adjusted EPS between $0.85 and $0.95.
The company aims to become a $1 billion business by 2030 by accelerating growth in its Specialty Nutrition Systems and Pain Management and Recovery segments, pursuing synergistic M&A, realizing operating efficiencies, and mitigating tariffs.
Avanos acquired the Nexus TKO needleless connector in September 2025, which was immediately accretive to revenue and generated $5 million in revenue over four months.
To mitigate an $18 million tariff headwind, Avanos is exiting China manufacturing by mid-2026 and implemented $15-$20 million in cost savings to be fully realized in 2026.

Jan 13, 2026, 10:15 PM

Transcript

Avanos Medical provides FY 2025 outlook and strategic vision at J.P. Morgan Healthcare Conference

AVNS

Guidance Update

M&A

New Projects/Investments

Avanos Medical projects FY 2025 Net Sales between $690-$700M and Adjusted EPS of $0.85-$0.95, with an anticipated $18M tariff headwind.
The company's strategic vision targets $1B in revenue by 2030, driven by accelerating growth in strategic segments and synergistic M&A opportunities.
The Nexus Medical Acquisition, closed on September 15, 2025, is expected to be immediately revenue and earnings accretive, adding approximately $5M of revenue to 2025.
Dave Pacitti, the recently appointed Chief Executive Officer with over 30 years of healthcare leadership, is executing on the company's strategic imperatives.

Jan 13, 2026, 10:15 PM

Presentation

Avanos Medical Reaffirms Guidance and Outlines Strategic Plan at J.P. Morgan Healthcare Conference

AVNS

Guidance Update

M&A

New Projects/Investments

Avanos Medical reaffirmed its full-year guidance for sales between $690 million and $700 million, expecting to finish on the upper end, and adjusted EPS between $0.85 and $0.95.
The company aims to achieve $1 billion in revenue by 2030 through a strategy focused on accelerating growth in its Specialty Nutrition Systems and Pain Management and Recovery segments, synergistic M&A, and operational efficiencies.
Avanos completed the acquisition of Nexus in September 2025, which generated $5 million in revenue over four months and was funded with cash. The company also announced $15-$20 million in cost savings to be fully realized in 2026.
As part of tariff mitigation, Avanos plans to exit China by mid-2026. Additionally, the NOPAIN Act, effective January 2025, now allows separate payment for its ON-Q and ambIT surgical pain pumps.

Jan 13, 2026, 10:15 PM

Transcript

Avanos Reports Q3 2025 Results and Updates 2025 Guidance

AVNS

Earnings

Guidance Update

M&A

Avanos reported net sales of $178 million and adjusted diluted earnings per share of $0.22 for the third quarter of 2025.
The company raised and narrowed its full-year 2025 revenue estimate to $690-$700 million and its adjusted EPS estimate to $0.85-$0.95 per share.
Strategic actions included the divestiture of the hyaluronic acid business on July 31 and the acquisition of Nexus Medical, which is expected to be immediately accretive to both revenue growth and earnings per share.
Avanos expects to achieve $15-$20 million of run-rate annualized incremental cost savings by the end of 2026, with $10 million in one-time cash charges anticipated in the fourth quarter of 2025.
The estimated P&L impact of incremental tariff-related manufacturing costs for 2025 is approximately $18 million, and the company anticipates generating $25-$30 million of free cash flow for the year.

Nov 5, 2025, 2:00 PM

Transcript

Avanos Medical Updates Full-Year 2025 Guidance and Reports Q3 2025 Results

AVNS

Guidance Update

Earnings

M&A

Avanos Medical raised and narrowed its full-year 2025 guidance, with Net Sales now estimated between $690 million and $700 million and Adjusted EPS between $0.85 and $0.95 per share.
For Q3 2025, the company reported Net Sales of $178 million and Adjusted EPS of $0.22.
The combined strategic segments, Specialty Nutrition Systems and Pain Management & Recovery, achieved 10% organic growth. Specialty Nutrition Systems Net Sales grew to $114 million in Q3 2025.
Avanos deployed capital into the acquisition of Nexus Medical and optimized its product portfolio with the sale of its Hyaluronic Acid product line. The company also expanded transformation initiatives to deliver $15 to $20 million of incremental annualized savings by the end of 2026.

Nov 5, 2025, 2:00 PM

Presentation

Avanos Medical, Inc. Announces Q3 2025 Results, Raises Full-Year Guidance, and Details Strategic Transactions

AVNS

Earnings

Guidance Update

M&A

Avanos Medical reported net sales of $177.8 million for Q3 2025, a 4.3% increase from the prior year, alongside a net loss of $1.4 million and diluted loss per share of $0.03.
Adjusted diluted earnings per share for Q3 2025 was $0.22, compared to $0.36 a year ago, and adjusted EBITDA was $20.2 million.
The company completed the acquisition of Nexus Medical and divested its HA product line during the quarter.
Avanos Medical raised and narrowed its full-year 2025 guidance, with estimated revenue now projected between $690 million and $700 million and adjusted diluted earnings per share between $0.85 and $0.95.

Nov 5, 2025, 12:01 PM

8-K

Avanos Medical, Inc. Announces Third Quarter 2025 Results and Updates Full-Year Guidance

AVNS

Earnings

Guidance Update

M&A

Avanos Medical reported third quarter 2025 net sales of $177.8 million, a 4.3% increase from the comparable prior year period, but recorded a net loss of $1.4 million and diluted loss per share of $0.03.
The Specialty Nutrition Systems (SNS) segment achieved net sales of $114.0 million in Q3 2025, driven by 14.0% volume growth.
For the nine months ended September 30, 2025, the company reported an operating loss of $64.1 million, which included a $77.0 million goodwill impairment charge in the second quarter within the Pain Management & Recovery (PM&R) segment.
Avanos completed the acquisition of Nexus Medical and divested its HA product line on July 31, 2025, as part of its strategic transformation.
The company raised and narrowed its 2025 estimated revenue guidance to between $690 million and $700 million and its adjusted diluted earnings per share guidance to a new range of $0.85 to $0.95.

Nov 5, 2025, 12:00 PM

Press Release

Avanos Medical Reports Q2 2025 Results, Announces Divestiture and Leadership Changes

AVNS

Earnings

CFO Change

M&A

Avanos Medical reported Q2 2025 net sales of $175.0 million, a 1.9% increase year-over-year, but a net loss of $76.8 million and diluted loss per share of $1.66, largely due to a $77.0 million goodwill impairment charge.
The company announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC on July 31, 2025, aligning with its strategy to focus on Pain Management & Recovery and Specialty Nutrition Systems.
Scott Galovan was appointed Senior Vice President, Chief Financial Officer, effective August 1, 2025, and CEO David Pacitti was appointed to the Board of Directors on the same date.
Avanos Medical maintained its 2025 estimated revenue guidance of $665 million to $685 million and adjusted diluted earnings per share guidance of $0.75 to $0.95.

Aug 5, 2025, 12:00 AM

8-K

Avanos Divests Hyaluronic Acid Product Line

AVNS

M&A

Avanos Medical, Inc. has divested its Hyaluronic Acid (HA) product line, which includes the TriVisc® and GenVisc® 850 injection products, to Channel-Markers Medical, LLC (CMM).
This transaction aligns with Avanos' ongoing transformation strategy, aimed at advancing its strategic segments in Pain Management & Recovery and Specialty Nutrition Systems.
Ownership of the HA product line officially transferred to CMM on July 31, 2025, with Avanos providing transition support through the end of 2025.